We are live on ! Find out more
TCM

Tekla Capital Management Portfolio holdings

AUM $2.56B
1-Year Est. Return 18.15%
This Fund
S&P 500
This Quarter Est. Return
+13.63%
1 Year Est. Return
+18.15%
3 Year Est. Return
+62.51%
5 Year Est. Return
+140.53%
10 Year Est. Return
+502.91%
AUM
$2.76B
AUM Growth
+$122M
Cap. Flow
-$172M
Cap. Flow %
-6.22%
Top 10 Hldgs %
38.62%
Holding
217
New
37
Increased
33
Reduced
47
Closed
5

Top Buys

Rank Stock Value
1
ZTS icon
Zoetis
ZTS
+$17M
2
JNJ icon
Johnson & Johnson
JNJ
+$13.8M
3
NVO
Novo Nordisk
NVO
+$8.1M
4
ELV icon
Elevance Health
ELV
+$7.92M
5
TMO icon
Thermo Fisher Scientific
TMO
+$6.37M

Top Sells

Rank Stock Value
1
MRK icon
Merck
MRK
+$42.7M
2
PFE icon
Pfizer
PFE
+$40.8M
3
VRTX icon
Vertex Pharmaceuticals
VRTX
+$30.9M
4
UNH icon
UnitedHealth
UNH
+$21M
5
LLY icon
Eli Lilly
LLY
+$17.4M

Sector Composition

Rank Sector Weight
1 Healthcare 93.74%
2 Real Estate 2.75%
3 Financials 0.62%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
BLUE
51
DELISTED
bluebird bio
BLUE
$12.8M 0.46%
6,777
+1,203
+22% +$2.49M
XBI icon
52
State Street SPDR S&P Biotech ETF
XBI
$10.3B
$12.4M 0.45%
129,000
-121,460
-48% -$11.8M
AMRN
53
Amarin Corp
AMRN
$298M
$12.3M 0.44%
37,702
+13,795
+58% +$1.04M
PVLA
54
Palvella Therapeutics
PVLA
$2.15B
$11.7M 0.42%
26,092
– –
BPMC
55
DELISTED
Blueprint Medicines
BPMC
$11.4M 0.41%
146,001
– –
DHC
56
Diversified Healthcare Trust
DHC
$2.17B
$11.4M 0.41%
646,554
– –
BAX icon
57
Baxter International
BAX
$13.8B
$11.3M 0.41%
146,040
+11,916
+9% +$884K
LKFT
58
Lakefront Biotherapeutics American Depositary Shares
LKFT
$1.81B
$11.2M 0.41%
99,815
+13,000
+15% +$1.37M
ALNY icon
59
Alnylam Pharmaceuticals
ALNY
$27.4B
$11M 0.4%
126,176
-4,200
-3% -$422K
MCK icon
60
McKesson
MCK
$101B
$11M 0.4%
82,947
-15,850
-16% -$2.07M
KYNB
61
Kyntra Bio
KYNB
$27.5M
$10.8M 0.39%
7,128
– –
FOLD
62
DELISTED
Amicus Therapeutics
FOLD
$10.6M 0.38%
875,304
– –
HCA icon
63
HCA Healthcare
HCA
$85.7B
$10.3M 0.38%
74,335
-755
-1% -$94K
COR icon
64
Cencora
COR
$60.7B
$10.3M 0.37%
111,807
+19,100
+21% +$1.65M
EXEL icon
65
Exelixis
EXEL
$14.1B
$9.82M 0.36%
553,940
+125,918
+29% +$2.46M
XLRN
66
DELISTED
Acceleron Pharma
XLRN
$9.77M 0.35%
170,766
– –
ACHC icon
67
Acadia Healthcare
ACHC
$2.62B
$9.59M 0.35%
272,400
– –
LTC
68
LTC Properties
LTC
$2.06B
$9.25M 0.34%
209,673
– –
GSK icon
69
GSK
GSK
$104B
$8.79M 0.32%
174,960
-112,240
-39% -$5.7M
DPLO
70
DELISTED
DIPLOMAT PHARMACY, INC.
DPLO
$8.52M 0.31%
439,001
– –
CI icon
71
Cigna
CI
$76.1B
$8.43M 0.31%
40,461
– –
ESPR
72
DELISTED
Esperion Therapeutics
ESPR
$8.4M 0.3%
189,287
– –
MRUS
73
DELISTED
Merus
MRUS
$8.18M 0.3%
414,115
– –
SNY icon
74
Sanofi
SNY
$103B
$8.04M 0.29%
179,900
– –
CRSP icon
75
CRISPR Therapeutics
CRSP
$4.77B
$7.91M 0.29%
178,348
– –
1 2
3
4 5

Similar funds

EST
EA Series Trust Havertown, Pennsylvania $2.84B AUM
VIA
Vident Investment Advisory Alpharetta, Georgia $2.9B AUM 24.67% 1-Year Est. Return
AWS
AJ Wealth Strategies New York $2.07B AUM 10.86% 1-Year Est. Return
JP
Jana Partners New York $1.34B AUM 4.95% 1-Year Est. Return
VCM
Vigilant Capital Management Portland, Maine $1.34B AUM 15.33% 1-Year Est. Return
FCFS
First Command Financial Services Fort Worth, Texas $1.06B AUM 10.74% 1-Year Est. Return
FCB
First Command Bank Fort Worth, Texas $1.06B AUM 10.74% 1-Year Est. Return
BWM
BerganKDV Wealth Management Bloomington, Minnesota $1,000M AUM 9.95% 1-Year Est. Return

Tekla Capital Management's Q3 2018 Portfolio in Review

As of Q3 2018, Tekla Capital Management held 217 positions worth $2.76B, up 4.6% from $2.64B the previous quarter. Its ten largest holdings account for 39% of the portfolio.

Tekla Capital Management withdrew a net $172M in Q3 2018, closing 5 positions and reducing 47 holdings. Its most notable exit was Welltower Inc., an estimated $11.9M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 94% of assets, up from 93% a quarter earlier, followed by Real Estate and Financials.

Against the trend, Tekla Capital Management opened a new position in Quest Diagnostics worth $4.21M.

  • Tekla Capital Management's largest Q3 2018 buy was Quest Diagnostics: 39,000 shares worth $4.21M.
  • Tekla Capital Management added most to Zoetis in Q3 2018, an estimated $17M increase.
  • Tekla Capital Management's biggest Q3 2018 reduction was Merck, cutting an estimated $42.7M.
  • Tekla Capital Management fully exited Welltower Inc. in Q3 2018, selling an estimated $11.9M.
  • Tekla Capital Management's ten largest holdings make up 39% of its $2.76B portfolio in Q3 2018.
  • Tekla Capital Management opened 37 new positions and closed 5 in Q3 2018.
  • Tekla Capital Management's portfolio value rose 4.6% quarter-over-quarter to $2.76B.

Based on Tekla Capital Management's 13F filing for Q3 2018, filed 13 Nov 2018.